Tokai Pharmaceuticals Inks $35.5m Series E

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $35.5 million in a Series E financing. The financing round included both current investors, Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.

North AmericaUSBriefs